DOCSLIB.ORG

Guidance Document

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidance Document Federal Institute for Drugs and Medical Devices PUBLIC ASSESSMENT REPORT Decentralised Procedure Scientific discussion during the initial procedure Gammadinone Betadinone Lamour Xidinone Epsilondinone Active Substance : Ethinylestradiol/Chlormadinone acetate Dosage Form : Film-coated tablets Procedure number DE/H/1606, 1607, 2349, 2374, 2375/001/DC Marketing authorisation holder in the Reference Member State, Germany : Helm Pharmaceuticals GmbH Nordkanalstr.28 20097 Hamburg, Germany Date: 25.02.2015 The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health. 1/8 Public AR TABLE OF CONTENTS I RECOMMENDATION .......................................................................................................... 3 II EXECUTIVE SUMMARY .................................................................................................... 3 II.1 Problem statement ..................................................................................................................... 3 II.2 About the product ..................................................................................................................... 3 II.3 General comments on the submitted dossier............................................................................. 3 II.4 General comments on compliance with GMP, GLP, GCP and agreed ethical principles. ....... 4 III SCIENTIFIC OVERVIEW AND DISCUSSION................................................................. 4 III.1 Quality aspects .......................................................................................................................... 4 Introduction ............................................................................................................................... 4 Drug substance .......................................................................................................................... 4 Drug Product ............................................................................................................................. 4 III.2 Nonclinical aspects ................................................................................................................... 5 III.3 Clinical aspects ......................................................................................................................... 5 Pharmacokinetics ...................................................................................................................... 5 Ethinyl estradiol ........................................................................................................................ 6 Chlormadinone acetate.............................................................................................................. 7 Study results for group A and additional group B .................................................................... 7 Pharmacodynamics ................................................................................................................... 7 Clinical efficacy ........................................................................................................................ 7 Clinical Safety ........................................................................................................................... 8 Pharmacovigilance system ........................................................................................................ 8 Risk Management Plan ............................................................................................................. 8 IV BENEFIT RISK ASSESSMENT ........................................................................................... 8 DE/H/1606/-07/2349/2374/2375/001/DC 2/8 Public AR Federal Institute for Drugs and Medical Devices I RECOMMENDATION Based on the review of the data on quality, safety and efficacy, the RMS considers that the application for Betadinone, with the indication “hormonal contraception” is approvable.. II EXECUTIVE SUMMARY II.1 Problem statement This decentralised application concerns a generic version of a combined oral contraceptive containing 2 mg chlormadinone acetate (CMA) and 0.03 mg ethinylestradiol (EE) per film-coated tablets, under the trade names Betadinone, Epsilodinone, Gammadinone, Lamour and Xidinone. The trade name Betadinone will be used in this Overview. II.2 About the product The contraceptive effect of the combination of CMA and EE is based on the interaction of various effects, the most important of which may be seen as the inhibition of ovulation and the changes in the cervical secretion. The progestational component of Betadinone, CMA, is an antiandrogenic progestogen which is structurally related to cyproterone acetate. The second component, Ethinylestradiol (EE), which is known since more than 60 years, is a synthetic steroid with high oral estrogenic potency and is used as the estrogen in most currently marketed combined oral contraceptives. The preparation applied for is a monophasic COC, given once daily at a fixed dose over the treatment cycle of 21 days followed by a 7-day “pill free” period. The therapeutic indication applied for is hormonal contraception and is identical with the indication licensed for the originator product, Belara. II.3 General comments on the submitted dossier The application is submitted under article 10 (1), generic application of Council Directive 2001/83/EC, as amended, claiming to be a generic to the reference product Belara 0.3 mg/2 mg film- coated tablets, Grünenthal Laboratories; Germany. Belara also contains 2 mg CMA and 0.03 mg EE per tablet and was approved in Germany on 30.11.1998 (MA no. 36579.00.00). The clinical overview describes and discusses pharmacodynamics, pharmacokinetics, efficacy and safety aspects of ethinylestradiol/chlormadinone acetate containing combinded oral contraceptives (COCs) based on published data. The list of literature cited gives an extensive overview of published articles dated from 1979 to 2008 concerning the components EE and CMA and oral contraception. Furthermore, the clinical overview summarizes the bioequivalence study. The results of one bioequivalence study have been submitted. The reference product used in this study was Belara, approved in Germany, manufactured by Grünenthal Laboratories, Germany. The bioequivalence study was performed in accordance with the CPMP Note for Guidance on Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98). No further clinical studies have been submitted and are not required for this type of application. The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health. 3/8 Public AR Federal Institute for Drugs and Medical Devices Together with the submitted documentation the information given in the submitted dossier is sufficient for this generic application. Additional data to be submitted as requested in the list of questions should be summarized and discussed in the Applicant´s responses and not only submitted as annexes including only the original statistical results without any table of contents or Applicant´s comment. II.4 General comments on compliance with GMP, GLP, GCP and agreed ethical principles. For manufacturing sites within the Community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites. For both active substances declarations from the Qualified Persons of the manufacturing holders in Section 2.5.1, responsible for batch release, are attached which confirm that all active substance manufacturers referred to in Section 2.5.3 operate in compliance with the detailed guidelines on good manufacturing practice for starting materials. The Applicant declares that this study was performed in compliance with good clinical practice (GCP), including the archiving of essential documents. There is no hint for non-compliance with GCP. III SCIENTIFIC OVERVIEW AND DISCUSSION III.1 Quality aspects Introduction The generic applications concern medicinal products containing 2 mg of EE and 0.03 mg CMA (FCT). The products are formulated as immediate release film coated tablets and are packaged in PVC/PVDC/Al blister. The documentation is of sufficient quality in view of the present European regulatory requirements. Drug substance The active substances CMA and EE are well known substances. The particle sizes are specified for both substances. The active drug substance CMA is described in French Pharmacopoeia (FPX) and Japanese Pharmacopoeia (JP). The manufacturer have submitted Active Substance Master Files (ASMF), based on the FPX and the JP monographs. The drug substance is controlled sufficiently. The control tests are adequately drawn up and the validation data are plausible. The available data show that CMA is stable for at least 5 years, if the samples are packed in a double polyethylene bag inside a fibre container. The quality of the drug substance EE is controlled in compliance with the recently implemented monograph of the European Pharmacopoeia (Ph. Eur.). For the EE manufacturer a Certificate of Suitability is presented documenting that the EE monograph is suitable to control the active substance purity. The micronisation step is discussed adequately. Drug Product The finished products Gammadinone, Betadinone, Lamour, Xidinone and Epsilondinone, film-coated tablets, contain 2 mg of CMA and 0.03 mg EE per film-coated tablet as drug substances each. The BfArM is a Federal Institute within the portfolio
Load more

Recommended publications
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Off Enders
    How to select pharmacologic treatments to manage recidivism risk in sex off enders Consider patient factors when choosing off -label hormonal and nonhormonal agents ® Dowden Healthex offenders Media traditionally are managed by the criminal justice system, but psychiatrists are fre- Squently called on to assess and treat these indi- CopyrightFor personalviduals. use Part only of the reason is the overlap of paraphilias (disorders of sexual preference) and sexual offending. Many sexual offenders do not meet DSM criteria for paraphilias,1 however, and individuals with paraphil- ias do not necessarily commit offenses or come into contact with the legal system. As clinicians, we may need to assess and treat a wide range of sexual issues, from persons with paraphilias who are self-referred and have no legal involvement, to recurrent sexual offenders who are at a high risk of repeat offending. Successfully managing sex offenders includes psychological and pharmacologic interven- 2009 © CORBIS / TIM PANNELL 2009 © CORBIS / tions and possibly incarceration and post-incarceration Bradley D. Booth, MD surveillance. This article focuses on pharmacologic in- Assistant professor terventions for male sexual offenders. Department of psychiatry Director of education Integrated Forensics Program University of Ottawa Reducing sexual drive Ottawa, ON, Canada Sex offending likely is the result of a complex inter- play of environment and psychological and biologic factors. The biology of sexual function provides nu- merous targets for pharmacologic intervention, in- cluding:2 • endocrine factors, such as testosterone • neurotransmitters, such as serotonin. The use of pharmacologic treatments for sex of- fenders is off-label, and evidence is limited. In general, Current Psychiatry 60 October 2009 pharmacologic treatments are geared toward reducing For mass reproduction, content licensing and permissions contact Dowden Health Media.
    [Show full text]
  • Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom
    No. LCMSMS-065E Liquid Chromatography Mass Spectrometry Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole No. LCMSMS-65E Mass Spectrometry This application news presents a method for the determination of 17 hormone residues in milk using Shimadzu Ultra-High-Performance Liquid Chromatograph (UHPLC) LC-30A and Triple Quadrupole Mass Spectrometer LCMS- 8040. After sample pretreatment, the compounds in the milk matrix were separated using UPLC LC-30A and analyzed via Triple Quadrupole Mass Spectrometer LCMS-8040. All 17 hormones displayed good linearity within their respective concentration range, with correlation coefficient in the range of 0.9974 and 0.9999. The RSD% of retention time and peak area of 17 hormones at the low-, mid- and high- concentrations were in the range of 0.0102-0.161% and 0.563-6.55% respectively, indicating good instrument precision. Method validation was conducted and the matrix spike recovery of milk ranged between 61.00-110.9%. The limit of quantitation was 0.14-0.975 g/kg, and it meets the requirement for detection of hormones in milk. Keywords: Hormones; Milk; Solid phase extraction; Ultra performance liquid chromatograph; Triple quadrupole mass spectrometry ■ Introduction Since 2008’s melamine-tainted milk scandal, the With reference to China’s national standard GB/T adulteration of milk powder has become a major 21981-2008 "Hormone Multi-Residue Detection food safety concern. In recent years, another case of Method for Animal-derived Food - LC-MS Method", dairy product safety is suspected to cause "infant a method utilizing solid phase extraction, ultra- sexual precocity" (also known as precocious puberty) performance liquid chromatography and triple and has become another major issue challenging the quadrupole mass spectrometry was developed for dairy industry in China.
    [Show full text]
  • Effects of 2 Mg Chlormadinone Acetate/0.03 Mg Ethinylestradiol In
    Journal für Reproduktionsmedizin und Endokrinologie – Journal of Reproductive Medicine and Endocrinology – Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie Effects of 2 mg Chlormadinone Acetate/0.03 mg Ethinylestradiol in Primary Dysmenorrhoea: The BEDY (Belara(R) Evaluation on Dysmenorrhea) Study - an Open Non-Comparative, Non-Interventional Observational Study with 4,842 Women Schramm GAK, Waldmann-Rex S J. Reproduktionsmed. Endokrinol 2010; 7 (Sonderheft 1), 112-118 www.kup.at/repromedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D·I·R, EFA, OEGRM, SRBM/DGE Indexed in EMBASE/Excerpta Medica/Scopus Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz Effects of CMA/EE in Primary Dysmenorrhoea Effects of 2 mg Chlormadinone Acetate/ 0.03 mg Ethinylestradiol in Primary Dysmenorrhoea: The BEDY (Belara® Evaluation on Dysmenorrhea) Study – an Open, Non-Comparative, Non-Interventional Observational Study with 4,842 Women G. A. K. Schramm, S. Waldmann-Rex Background: This prospective, non-interventional, observational study designed to reflect the daily medical practice which is very important for the product observation liability investigated the effects of 2.0 mg chlormadinone acetate/0.03 mg ethinylestradiol (CMA/EE) on dysmenorrhoea and related problems. Study design: A total of 4,842 patients were observed during a six-cycle period (26,945.5 treatment cycles) in 608 office-based gynaecological centres throughout Germany. Results: The administration of CMA/EE significantly reduced the number of patients who suffered from menstrual pain (–50.4 %). Analgesic use and absenteeism from school or work due to dysmenorrhoea was reduced by 74.6 % in OC starters and 91.9 % in OC switchers.
    [Show full text]
  • Progestogens and Venous Thromboembolism Among Postmenopausal Women Using Hormone Therapy. Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin
    Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin To cite this version: Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin. Progestogens and venous throm- boembolism among postmenopausal women using hormone therapy.. Maturitas, Elsevier, 2011, 70 (4), pp.354-60. 10.1016/j.maturitas.2011.10.002. inserm-01148705 HAL Id: inserm-01148705 https://www.hal.inserm.fr/inserm-01148705 Submitted on 5 May 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Progestogens and VTE Finale version Progestogens and venous thromboembolism among postmenopausal women using hormone therapy Marianne Canonico1,2, Geneviève Plu-Bureau1,3 and Pierre-Yves Scarabin1,2 1 Centre for Research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular Disease 2 University Paris-Sud, UMR-S 1018, Villejuif, France 3 University Paris Descartes and Hôtel-Dieu Hospital, Paris, France Adresse: 16 av. Paul Vaillant Couturier 94807 Villejuif Cedex Tel: +33 1 45 59 51 66 Fax: +33 1 45 59 51 70 Corresponding author: Marianne Canonico ([email protected]) 1/21 Progestogens and VTE Finale version Abstract Hormone therapy (HT) is the most effective treatment for correcting menopausal symptoms after menopause.
    [Show full text]
  • Long-Term Menopausal Treatment Using an Ultra-High Dosage of Tibolone in an Elderly Chinese Patient – Case Report
    Long-term menopausal treatment using an ultra-high dosage of tibolone in an elderly Chinese patient – Case report Lingyan Zhang 1, Xiangyan Ruan 1,2*, Muqing Gu 1, Alfred O. Mueck 1,2 1 Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China; 2 Department of Women’s Health, University Women’s Hospital and Research Centre for Women’s Health, University of Tuebingen, Tuebingen D-72076, Germany) ABSTRACT This report describes the special case of a Chinese woman with severe vasomotor symptoms (VSMs), depressed mood, low energy and genitourinary syndrome of menopause, including problems of sexual dysfunction, who was treated with tibolone. The aim of the report is to highlight the value of individualizing menopausal hormone therapy (MHT) type and dosage. Since 16 years of previous treatment with various other forms of MHT had not provided satisfactory efficacy in this patient, at the age of 71 years she was prescribed tibolone, starting at the usual lowest dosage of 1.25 mg/day. We gradually had to increase the dosage of tibolone up to 7.5 mg/day, which is three-fold the recommended maximum dosage. We added three-monthly sequential dydrogesterone to reduce the risk of breakthrough bleeding and the risk of endometrial cancer. To date, we have observed no side effects and no remarkable abnormal laboratory assessments, with the exception of increased thyroid-stimulating hormone, which we monitor six-monthly. Even though the patient has been informed about potential risks, such as increased risks of stroke, breast cancer and endometrial cancer, as described in the discussion, she has now been willing to accept this ultra-high dosage for seven years, and wishes to continue with this treatment.
    [Show full text]
  • Role of Androgens, Progestins and Tibolone in the Treatment of Menopausal Symptoms: a Review of the Clinical Evidence
    REVIEW Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence Maria Garefalakis Abstract: Estrogen-containing hormone therapy (HT) is the most widely prescribed and well- Martha Hickey established treatment for menopausal symptoms. High quality evidence confi rms that estrogen effectively treats hot fl ushes, night sweats and vaginal dryness. Progestins are combined with School of Women’s and Infants’ Health The University of Western Australia, estrogen to prevent endometrial hyperplasia and are sometimes used alone for hot fl ushes, King Edward Memorial Hospital, but are less effective than estrogen for this purpose. Data are confl icting regarding the role of Subiaco, Western Australia, Australia androgens for improving libido and well-being. The synthetic steroid tibolone is widely used in Europe and Australasia and effectively treats hot fl ushes and vaginal dryness. Tibolone may improve libido more effectively than estrogen containing HT in some women. We summarize the data from studies addressing the effi cacy, benefi ts, and risks of androgens, progestins and tibolone in the treatment of menopausal symptoms. Keywords: androgens, testosterone, progestins, tibolone, menopause, therapeutic Introduction Therapeutic estrogens include conjugated equine estrogens, synthetically derived piperazine estrone sulphate, estriol, dienoestrol, micronized estradiol and estradiol valerate. Estradiol may also be given transdermally as a patch or gel, as a slow release percutaneous implant, and more recently as an intranasal spray. Intravaginal estrogens include topical estradiol in the form of a ring or pessary, estriol in pessary or cream form, dienoestrol and conjugated estrogens in the form of creams. In some countries there is increasing prescribing of a combination of estradiol, estrone, and estriol as buccal lozenges or ‘troches’, which are formulated by private compounding pharmacists.
    [Show full text]
  • Cyproterone Acetate and Ethinyl Estradiol
    CYPROTERONE ACETATE + ETHINYLESTRADIOL Class: Acne Products; Estrogen and Progestin Combination Indications: Treatment of females with severe acne, unresponsive to oral antibiotics and other therapies, with associated symptoms of androgenization (including mild hirsutism or seborrhea). Should not be used solely for contraception; however, will provide reliable contraception if taken as recommended for approved indications Available dosage form in the hospital: CYPROTERONE ACETATE 2MG + ETHINYLESTRADIOL 0.035MGTAB Trade Names: Dosage: Females: Acne: Oral: One tablet daily for 21 days, followed by 7 days off; first cycle should begin on the first day of menstrual flow. Subsequent dosing cycles should begin on the same day of the week that the first cycle was begun regardless of presence of withdrawal bleeding. Discontinue therapy 3-4 cycles after symptoms have resolved. Note: Retreatment may be considered with recurrence of symptoms following therapy discontinuation. Renal Impairment: Specific guidelines not available; use with caution. Hepatic Impairment: Contraindicated in hepatic impairment or active liver disease. Common side effect: Note: This listing reflects reactions reported with combination hormonal contraceptives. Percentages specific to this combination are identified in parentheses. -Cardiovascular: Varicosities (3%), edema (2%), arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, hypertension, mesenteric thrombosis, MI, Raynaud’s phenomenon -Central nervous system: Headache (5%), nervousness (4%), depression
    [Show full text]
  • Use of Oral Contraceptives in the Management of Acne
    Open Access Journal of Contraception Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Use of oral contraceptives in the management of acne Gian Benedetto Melis Abstract: The pathogenesis of acne (the most common disorder involving the sebaceous gland) Marisa Orrù originates from increased sebum production by the sebaceous gland followed by colonization Maria Francesca Marotto of the hair follicle with Propionibacterium acnes, hyperkeratinization of the upper follicle, and Monica Pilloni release of inflammatory mediators into the skin. Androgens are the main stimulators of sebum Mariagrazia Perseu production. Androgens originate from the gonads and adrenal glands, but can also be locally Stefano Lello produced within the sebaceous gland from dehydroepiandrosterone sulfate. In the presence of high androgen levels, which can be either a normal pattern of adolescence or a consequence of Anna Maria Paoletti gonadal or adrenal disease, overproduction of sebum triggers the pathogenesis of acne which, Clinica Ginecologica Ostetrica e di mainly in adolescent women, has deleterious psychological consequences. Estrogens exert the Fisiopatologia della Riproduzione For personal use only. Umana, Universita’ di Cagliari, Azienda opposite action on sebum production, probably due to the reduction of androgen availability, Ospedaliero Universitaria di Cagliari, a direct consequence of estrogen-related increased production of hepatic sex hormone-binding Cagliari, Italy globulin (SHBG). The inhibition of the hypothalamus-pituitary axis induced by oral contra- ceptives is followed by reduced androgen production. Oral contraceptives containing ethinyl estradiol, which has strong estrogenic activity, amplify the hypoandrogenic effect via estrogen- related stimulation of SHBG. The hypoandrogenic effect of oral contraceptives is modulated by the progestin compound.
    [Show full text]
  • Multi-Discipline Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212099Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA 212099 Multi-disciplinary Review and Evaluation Darolutamide/NUBEQA NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) 212099 Priority or Standard Priority Submit Date(s) February 26, 2019 Received Date(s) February 26. 2019 PDUFA Goal Date August 26, 2019 Division/Office Division of Oncology Products 1/Office of Hematology & Oncology Products Review Completion Date Established/Proper Name Darolutamide (Proposed) Trade Name Nubeqa Pharmacologic Class Androgen receptor inhibitor Code name 427492003 | Hormone refractory prostate cancer (disorder) Applicant Bayer Doseage form 300 mg tablets Applicant proposed Dosing NUBEQA 600 mg, (two 300 mg tablets) administered orally Regimen twice daily. Swallow tablets whole. Take NUBEQA with food. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Applicant Proposed NUBEQA is an androgen receptor inhibitor indicated for the Indication(s)/Population(s) treatment of patients with non-metastatic castration-resistant prostate cancer. Applicant Proposed Non-metastatic castration resistant prostate cancer (nmCRPC) SNOMED CT Indication Disease Term for each Proposed Indication Recommendation on Regular approval Regulatory Action Recommended
    [Show full text]
  • Summary of Product Characteristics, Labelling and Package Leaflet
    SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 1 SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT <invented name> 2 mg/0.03 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 2 mg of chlormadinone acetate and 0.03 mg of ethinyl estradiol. Excipient with known effects: One coated tablet contains 75.27 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Tablets are biconvex, pink and rounded. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Hormonal contraception The decision to prescribe <invented name> should take into consideration the individual woman’s current risk factor, particularly those for venous thromboembolism (VTE), and how the risk of VTE with <invented name> compares with other CHCs (see sections 4.3 and 4.4). 4.2 Posology and method of administration Administration of the film-coated tablets One film-coated tablet should be taken daily, at the same time (preferably at night) for 21 consecutive days, followed by a 7-day tablet-free period; withdrawal bleeding, similar to menstruation, should occur two to four days after the administration of the last tablet. The tablets should be resumed after the 7-day rest period, using the following blister of <invented name>, regardless of whether the bleeding has ceased or not.
    [Show full text]